Humanized anti-IL-4Rα single domain antibodies and uses thereof
Humanized anti-IL-4Rα antibodies address the limitations of current treatments by specifically targeting IL-4Rα, effectively inhibiting type 2 inflammation and improving treatment efficacy for allergic diseases with reduced side effects.
Patent Information
- Application Number
- JP2022580486
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-12-09
- Filing Date
- 2021-02-24
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2041-02-24
AI Technical Summary
Current treatments for type 2 inflammatory diseases, such as asthma and atopic dermatitis, often rely on broad-spectrum immunosuppressants that have significant side effects and do not target the underlying immune pathways effectively, while targeted therapies like omalizumab fail to provide substantial clinical benefits due to the complexity of type 2 inflammation.
Development of humanized anti-IL-4Rα single domain antibodies that specifically target the IL-4Rα receptor, reducing immunological side effects and enhancing therapeutic efficacy by inhibiting key upstream drivers of type 2 inflammatory pathways.
The humanized anti-IL-4Rα antibodies effectively neutralize IL-4 and IL-13 signaling, offering improved treatment outcomes with reduced side effects and targeted therapeutic benefits for allergic diseases.
Smart Images

Figure 0007590785000012 
Figure 0007590785000013 
Figure 0007590785000014
Abstract
Description
[Technical field]
[0001] The present invention relates to the technical field of antibodies, in particular to a humanized anti-IL-4Rα single domain antibody and uses thereof. [Background technology]
[0002] The type 2 inflammatory response in the human body is caused by type 2 helper T cells (T helper 2, TH2). Such type 2 inflammatory responses have a unified characteristic and are therefore called allergic diseases, such as asthma and various other inflammatory diseases. Conventional methods of inflammation suppression generally use broad-spectrum immunosuppressants to suppress the suffering of diseases, or target drugs that specifically target downstream products of TH2 cells, such as IgE, to treat diseases. Compared with conventional treatment methods, treatment methods targeting type 2 cytokines (IL-4, IL-5, IL-13) secreted by TH2 cells have already shown great potential in the treatment of various immune diseases, and patients can obtain better therapeutic outcomes. After several disappointing clinical results with treatment methods targeting IL-4, IL-5, or IL-13 in asthma patients, researchers have used personalized methods and have obtained therapeutic effects in asthma subtypes that exhibit an "allergic" phenotype. Recently, the therapeutic effects have been extended to a wider range of asthma patients. This indicates that type 2 inflammation is closely related to severe asthma patients if key upstream drivers in the signaling pathway are appropriately inhibited. In addition, simultaneous inhibition of IL-4 and IL-13 has shown therapeutic efficacy in diseases commonly associated with asthma, such as atopic dermatitis and chronic sinusitis including nasal polyps, supporting the hypothesis that targeting key "driver pathways" may be therapeutically effective in many allergic diseases.
[0003] Allergic diseases have become widespread worldwide, and epidemiological studies have shown that the prevalence of food allergies, rhinoconjunctivitis, atopic dermatitis, and asthma is increasing. Allergy is a systemic type 2 inflammatory response to harmless antigens (allergens) that arises from a complex interplay of genetic and environmental factors. The response ultimately leads to increased production of immunoglobulin E (IgE) and various inflammatory immune responses. Severity can vary from patient to patient, ranging from mild harm to potentially life-threatening, and involves single or multiple organ systems and tissues. Allergic diseases can appear quite different due to their unique organ and tissue manifestations, and are usually treated by clinicians from different medical specialties. However, the tendency of many allergic diseases to develop simultaneously or progressively (i.e., the "topic march") suggests that they may share common underlying drivers. In line with these ideas, it has long been known that type 2 helper T cell-mediated type 2 inflammatory responses are also important in both asthma and atopic dermatitis, two highly prevalent chronic diseases that display distinct tissue-specific expression in the lung and skin, respectively.
[0004] Although early clinical studies with type 2 pathway modulators have been somewhat disappointing, clinical data from patients with allergic asthma (as identified by biomarkers) support the important role of three specific type 2 cytokines: interleukin 5 (IL-5) and its co-receptor sister cytokines IL-4 and IL-13 (Figure 1). Treatment with the IL-5-specific humanized monoclonal antibody (mAb) mepolizumab (GlaxoSmithKline) has shown efficacy in some patients with asthma and chronic rhinosinusitis with nasal polyposis (CSwNP). Simultaneous inhibition of IL-4 and IL-13 signaling with a fully humanized IL-4 receptor subunit alpha (IL-4Rα) blocking antibody (dupilumab, Regeneron / Sanofi) has been shown to be therapeutically effective in three allergic diseases: atopic dermatitis, CSwNP, and asthma. These latest clinical data suggest that targeting key central "drivers" may offer the intriguing possibility of substantial therapeutic benefit in allergic diseases characterized by various organ-specific clinical manifestations. It is now time to define and classify allergic diseases and tailor therapeutic approaches according to common immune pathways.
[0005] The dominance of type 2 inflammation is a key driver of allergic diseases. The type of antigen, combined with environmental and potentially genetic factors, influences the release of various cytokines, leading innate immune and lymphoid cells to induce or propagate type 2 inflammatory processes. At the barrier interface with environmental stimuli, epithelial-derived cytokines, such as IL-25, IL-33, and thymic stromal lymphopoietin (TSLP), can initiate type 2 immune responses or amplify existing type 2 inflammation. These upstream mediators stimulate the production of type 2 cytokines by innate cells and also contribute to the polarization of naive T cells towards CD4+TH2 cells. TH lymphocyte subsets are classified according to immune responses associated with specific cytokines and inflammatory mediators specific to each subset, for example, TH1 cells produce interferon-γ (IFNγ), TH2 cells produce IL-4, IL-5 and IL-13, TH9 cells produce IL-9, TH17 cells produce IL-17A, IL-17F, IL-21 and IL22, TH22 cells produce IL-22, and regulatory T cells (TREG) can produce IL-10. Among other actions, TH2 cells induce B cell proliferation and then undergo a stage of antibody type switching, resulting in high levels of circulating IgE. Thus, IgE is an important downstream biomarker of TH2 cell activation. IgE binds to the high affinity IgE receptor (FcεRI) found on basophils and mast cells, and cross-linking of IgE in these cells leads to cell activation and degranulation of various inflammatory mediators. These inflammatory mediators include histamine, prostaglandins and other proinflammatory cytokines (e.g., IL-4, IL-5 and IL-13), thus amplifying the type 2 response. In the lower respiratory tract, this type 2 inflammatory environment leads to an increase in eosinophils, mucus production and smooth muscle contraction. Although these processes are important protective immune functions to eliminate parasitic infections, they also have a pathological role against harmless antigens or allergens, resulting in allergy.
[0006] In addition to classically defined allergic diseases (including asthma, atopic dermatitis, food allergies, allergic rhinitis and conjunctivitis), a variety of diseases of unknown etiology also show type 2 clinical features (most notably eosinophilia and / or high serum IgE levels), including chronic idiopathic urticaria, CSwNP and eosinophilic esophagitis.
[0007] Some allergic diseases (e.g., allergic rhinitis) respond well to the combination of antihistamines and specific immunotherapy, whereas nonspecific immunosuppression is the primary treatment for more severe allergic diseases (e.g., atopic dermatitis and asthma), but in both cases, an abnormal inflammatory response develops and the disease symptoms propagate. Reducing inflammation with broad-spectrum immunosuppressants systemically (e.g., corticosteroids, cyclosporine A, methotrexate, azathioprine, or mycophenolate mofetil, given orally or intravenously), is effective in alleviating severe symptoms. The immunosuppressive activity of these drugs occurs by targeting downstream mediators such as transcription factors. For example, corticosteroids bind to the glucocorticoid receptor and suppress the expression of key transcription factors such as nuclear factor-κB (NF-κB), which drive inflammation. Cyclosporine A is a calcineurin inhibitor that can prevent the production of IL-2, which is required for T cell activation and proliferation (by the transcription factor nuclear factor of activated T cells (NFAT)). However, due to the broad mechanism of action of cyclosporine A and corticosteroids, systemic immunosuppressive therapy can have pleiotropic effects, resulting in toxicity, such as fluid retention, glucose intolerance, hypertension, muscle weakness, poor gastrointestinal tolerance, potential bone loss, suppression of the hypothalamic-pituitary-adrenal axis, and increased susceptibility to infection. Although local administration (i.e., inhaled medications, topical drops, nasal sprays, or creams) can reduce the side effects of these immunosuppressants, local immunosuppression is insufficient to treat the more severe forms of these diseases. Thus, there is still a great need for more specific therapeutic approaches.
[0008] Using brute force measures to suppress inflammation does not provide insight into which immune pathways drive and propagate disease. For example, the broad-acting drug cyclosporine A is effective in treating psoriasis and atopic dermatitis. Meanwhile, the different clinical effects of specifically targeting tumor necrosis factor (TNF) in psoriasis and atopic dermatitis suggest that the two skin diseases have different driving pathways. Although TNF inhibitors have been approved for the treatment of psoriasis, their sustained efficacy in atopic dermatitis (a type 2 inflammation-driven disease) has yet to be demonstrated.
[0009] Omalizumab (Xolair, Novartis / Genentech) induces more specific immunosuppression in allergic diseases by targeting IgE, the final mediator of type 2 inflammation and a potent trigger of mast cell and basophil degranulation. This IgE-specific humanized monoclonal antibody is the first monoclonal antibody treatment to receive regulatory approval for asthma, but is ineffective against atopic dermatitis. Omalizumab has been shown to reduce free serum IgE levels and reduce exacerbations through the novel anti-inflammatory mechanism described above, but has little effect on forced expiratory volume in 1 second (FEV1), a measure of lung function. Omalizumab can also improve symptoms of complicated CSwNP and is approved for the treatment of chronic idiopathic urticaria refractory to antihistamines. In pivotal trials, omalizumab showed significant improvements in terms of pruritus and disease activity endpoints. On the other hand, in atopic dermatitis, a reduction in serum free IgE levels is insufficient to obtain a good clinical response. Treatment of patients with moderate atopic dermatitis with omalizumab for 16 weeks did not improve disease endpoints (eczema area and severity index (EASI), and investigator global assessment). In addition, the pruritus scores of treated patients were slightly worse than those of the placebo group. These results indicate that even in type 2 inflammation-driven diseases, the disease regulator is not uniformly IgE, the end product of the TH2 pathway.
[0010] To achieve optimal therapeutic outcomes in various allergic diseases, it may be necessary to target key upstream drivers of the type 2 inflammatory pathway rather than downstream mediators. To this end, three key type 2 cytokines, IL-4, IL-5 and IL-13, are promising candidates for common nodes in allergic inflammatory diseases.
[0011] IL-4 is a key differentiation factor driving TH2-type responses. IL-4 triggers the differentiation of T cells into the TH2 subset and induces the production of type 2-associated cytokines and chemokines, such as IL-5, IL-9, IL-13, TARC, and eosinophil chemokines. In B cells, IL-4 induces isotype switching to IgE. In vitro, IL-4 promotes the differentiation of TH naive T cells into type 2 helper T cells. In vivo, IL-4 deficiency inhibits the production of type 2 cytokines in response to parasitic infection. On the other hand, IL-4 negatively regulates TH1-type responses associated with IFNγ production, activation of macrophage cells, thereby maintaining immunological polarization towards type 2 responses.
[0012] IL-4 and IL-13 are potent mediators of type 2 immunity with overlapping yet distinct functions related to their receptor expression patterns. Although IL-4 and IL-13 share only 25% amino acid homology, these cytokines share a common receptor moiety, IL-4Rα, which binds to a unique accessory chain to induce signal transduction. IL-4Rα is expressed on both hematopoietic and non-hematopoietic cells, but the differential expression of the accessory chain on different cell types reveals their functional differences (Figure 1). The type 1 receptor consists of IL-4Rα and a common γ chain, the latter of which is present only on hematopoietic cells. The type 2 receptor complex consists of IL-4Rα and IL-13Rα1, the latter of which is present on many non-hematopoietic cells, such as keratinocytes, hair follicles, epidermal sebaceous and sweat glands, nasal and bronchial epithelial cells, smooth muscle cells, and fibroblasts. IL-4 signals through type 1 and type 2 receptor complexes, whereas IL-13 signals exclusively through the type 2 receptor complex, because IL-13 binds to its own major binding chain (IL-13Rα1), whereas IL-4 binds primarily to IL-4Rα.
[0013] The two cytokines have different potencies and signaling kinetics. The high binding of IL-4 to IL-4Rα is independent of the affinity of binding (KD) of the gamma chain or IL-13Rα1, but the presence of IL-4Rα increases the affinity of IL-13 to IL-13Rα1 (KD from 10 mM to 30 pM). The type 2 receptor for IL-4 also has a faster time course of involvement in activated intracellular signaling than IL-13. Careful inspection of these phenotypes supports the hypothesis that IL-4 is a central mediator of T2 cell differentiation, B cell development, initiation of isotype class switching (especially IgE) and eosinophil recruitment in mouse models of parasitic infection and allergy. Although IL-13 has some redundancy in these proinflammatory processes, IL-13 also has other roles in mediating goblet cell hyperplasia and smooth muscle contraction, which may be related to the unique expression pattern of the type 2 receptor complex and local cytokine production.
[0014] Both IL-4 and IL-13 mediate IgE production through their activity on B cells. Knockout of IL-4 or IL-13 in mice results in severe defects in IgE production in response to allergen challenge. IL-4 can initiate and promote isotype switching and B cell development, but there is evidence that IL-13 can also bind to activated human B cells, suggesting that IL-13 contributes to sustaining IgE production and providing an interpretation of the phenotypes observed in gene knockout mice.
[0015] IL-4, IL-5 and IL-13 can promote type 2 inflammatory tissue and blood eosinophils. IL-5 is an effective eosinophil cytokine, involved in bone marrow growth and differentiation, survival and mobilization, and migration from bone marrow to blood. IL-5 binds to the cytokine-specific subunit receptor IL-5Rα, which complexes with a shared signaling subunit β chain. Granulocyte-macrophage colony-stimulating factor (GM-SCF) and IL-3 also require β chain signaling. IL-5Rα is highly expressed on eosinophils and eosinophil precursor cells, and is also present on basophils. In the absence of IL-5 (in gene knockout or after treatment with IL-5-specific antibodies), blood and tissue eosinophil responses to allergen challenge are abrogated.
[0016] The production of type 2 upstream cytokines can be promoted by the epithelium-derived cytokines IL-25, IL-33, and TSLP, which may be released at the barrier interface after tissue injury or allergen exposure. The activity of these epithelium-derived cytokines on various innate cell types (e.g., type 2 innate lymphoid cells and mast cells) can induce the production of IL-4, IL-5, and IL-13, and can also promote TH2-type responses. In particular, IL-33, when functioning as an "alarmin" (a signal of cell or tissue damage), can polarize naive T cells into TH2 cells and amplify existing type 2 responses. IL-33 also induces the production of high levels of type 2 cytokines, especially IL-5 and IL-13, in innate lymphoid cells together with IL-25. TSLP promotes the production of cytokines in basophils, monocytes, and natural killer T cells, and also activates dendritic cells to prime and activate TH2 cells.
[0017] In conclusion, IL-4, IL-5 and IL-13 have pleiotropic effects and play different roles in modulating type 2 immune responses and driving type 2 and TH2 pathway activation markers, i.e. IgE production and eosinophilia. Preclinical data provide strong evidence that both asthma and atopic dermatitis are driven by these mediators of type 2 inflammation. Transgenic mice overexpressing all three type 2 cytokines, IL-4, IL-5 and IL-13, spontaneously developed asthma-like lung disease and atopic dermatitis-like skin disease characterized by an exaggerated type 2 response with high serum IgE levels, extensive cellular infiltration in the skin and lungs (including eosinophils and lymphocytes), skin thickening and airway epithelial hypertrophy. Further studies will show that IL-4 and IL-13 are each sufficient independently to cause similar pathologies. These preclinical data suggest that IL-4 and IL-13 are important proximal disease drivers.
[0018] A humanized antibody is an antibody that is mainly produced by modifying and re-expressing a non-human monoclonal antibody through gene cloning and DNA recombination techniques, and most of the amino acid sequence is replaced with a sequence of human origin, so that the affinity and specificity of the parent monoclonal antibody are substantially maintained while the heterogeneity is reduced, which is advantageous for use in humans. However, there is currently a lack of humanized camelid single domain antibodies that target IL-4Rα. Summary of the Invention [Problem to be solved by the invention]
[0019] The object of the present invention is to provide a humanized anti-IL-4Rα single domain antibody and its use. The anti-IL-4Rα single domain antibody provided by the present invention is modified by humanization, and has affinity and tumor cell proliferation inhibitory effect, while effectively reducing immune side effects. [Means for solving the problem]
[0020] The present invention is realized as follows.
[0021] In one aspect, the present invention provides a humanized anti-IL-4Rα single domain antibody having complementarity determining regions comprising CDR1, CDR2 and CDR3, and framework regions comprising FR1, FR2, FR3 and FR4.
[0022] The amino acid sequence of CDR1 is shown in SEQ ID NO:3, the amino acid sequence of CDR2 is shown in SEQ ID NO:12, and the amino acid sequence of CDR3 is shown in SEQ ID NO:18.
[0023] The amino acid sequence of FR1 is shown in SEQ ID NO: 2, the amino acid sequence of FR2 is selected from any of SEQ ID NOs: 4 to 11, the amino acid sequence of FR3 is selected from any of SEQ ID NOs: 13 to 17, and the amino acid sequence of FR4 is shown in SEQ ID NO: 20 or 21.
[0024] The inventors of the present invention have scientifically and rationally humanized the camel-derived anti-IL-4Rα single domain antibody of sequence number 22 at appropriate positions to obtain a humanized anti-IL-4Rα single domain antibody that retains affinity and tumor cell proliferation inhibitory effect while effectively reducing immune side effects.
[0025] The above-mentioned complementarity determining regions and frameworks are linked in the order of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 to form the primary sequence structure of the single domain antibody of the present invention.
[0026] In an alternative embodiment, the amino acid sequence of FR2 is set forth in SEQ ID NO:11, the amino acid sequence of FR3 is set forth in SEQ ID NO:15, and the amino acid sequence of FR4 is set forth in SEQ ID NO:21.
[0027] Compared with other humanized single domain antibodies, the single domain antibody of the embodiment has higher affinity and lower immune side effects, demonstrating better technical efficacy.
[0028] In a further aspect, the present invention provides a fusion protein comprising the anti-IL-4Rα single domain antibody described above.
[0029] The single domain antibody provided in the present invention can be fused with any other proteins or substances to achieve different purposes, for example, conjugated with fluorescent proteins, enzymes or radioactive elements for easy detection, or fused with drug molecules for treating diseases related to the mediation of IL-4Rα for better treatment. The types of proteins fused with the single domain antibody can be reasonably selected by those skilled in the art according to actual needs or purposes, and all the obtained fusion proteins fall within the protection scope of the present invention, regardless of the types of substances fused with the single domain antibody.
[0030] In a further aspect, the present invention provides a bispecific antibody comprising the anti-IL-4Rα single domain antibody described above.
[0031] Based on the sequence or structure of the single domain antibody provided by the present invention, a person skilled in the art can easily conceive and easily realize fusing it with other specific antibodies to obtain bispecific or multispecific antibodies capable of specifically binding to two or more antigens. Therefore, regardless of the antibody to be fused, all bispecific antibodies obtained as described above fall within the scope of protection of the present invention.
[0032] In a further aspect, the present invention provides the use of an anti-IL-4Rα single domain antibody as described above, a fusion protein as described above, or a bispecific antibody as described above in the preparation of a drug targeting IL-4Rα for the treatment of a disease.
[0033] The single domain antibodies, fusion proteins and bispecific antibodies provided herein are applicable to any disease in which IL-4Rα is a therapeutic target, including, but not limited to, asthma, allergic dermatitis, eczema, arthritis, herpes, chronic idiopathic urticaria, scleroderma, hypertrophic scars, chronic obstructive pulmonary disease, atopic dermatitis, idiopathic pulmonary fibrosis, Kawasaki disease, sickle cell disease, Graves' disease, Sjogren's syndrome, autoimmune lymphoproliferative syndrome, autoimmune hemolytic anemia, Barrett's esophagus, autoimmune uveitis, tuberculosis, and kidney disease.
[0034] In a further aspect, the present invention provides a medicament for treating a disease comprising the above-described anti-IL-4Rα single domain antibody, the above-described fusion protein, or the above-described bispecific antibody, and a pharma- ceutically acceptable excipient.
[0035] The above-mentioned pharma- ceutically acceptable excipients are, for example, pharmaceutical excipients in the pharmaceutical field, such as diluents, fillers, binders, wetting agents, absorption enhancers, surfactants, disintegrants, adsorption carriers, lubricants, etc. Other excipients, such as flavoring agents and sweeteners, may also be added. That is, the excipients are one or more of diluents, fillers, binders, wetting agents, absorption enhancers, surfactants, disintegrants, adsorption carriers, lubricants, flavoring agents, and sweeteners, and those skilled in the art can rationally select them as necessary.
[0036] In a further aspect, the present invention provides an isolated nucleic acid molecule encoding the above-described anti-IL-4Rα single domain antibody.
[0037] It should be noted that, based on the disclosure of the present invention, a person skilled in the art can easily obtain a polynucleotide molecule encoding the above-mentioned single domain antibody and fusion protein by using common techniques in this field; and due to the degeneracy of the code, the polynucleic acid molecule is variable and its specific base sequence may vary. Therefore, regardless of the change in the polynucleic acid molecule, as long as it can encode the single domain antibody or fusion protein of the present invention, the nucleic acid molecule falls within the scope of protection of the present invention.
[0038] In a further aspect, the present invention provides a vector or recombinant cell comprising the above-described nucleic acid molecule.
[0039] In a further aspect, the present invention provides a method for preparing an anti-IL-4Rα single domain antibody as described above, the method comprising the steps of culturing a recombinant cell and isolating and purifying said single domain antibody from the culture product, said recombinant cell comprising a recombinant expression vector comprising the nucleic acid molecule as described above.
[0040] It should be explained that the preparation of the single domain antibodies, fusion proteins and antibodies of the present invention may be realized by chemical synthesis methods, genetic engineering techniques or other methods. All the single domain antibodies, fusion proteins or antibodies described in the present invention are within the protection scope of the present invention, regardless of their preparation methods.
[0041] In order to more clearly describe the technical solutions of the embodiments of the present invention, the following briefly describes the drawings used in the embodiments. The following drawings only illustrate some embodiments of the present invention, and should not be regarded as limiting the scope, and it should be understood that those skilled in the art can think of other related drawings based on these drawings without creative efforts. [Brief description of the drawings]
[0042] [Figure 1] FIG. 1 is a schematic diagram of the IL4 / IL-13 and IL-5 signaling pathways. [Diagram 2] 1 shows a comparison of the sequences of several clones of the anti-IL-4Rα monoclonal antibody 4E9 after humanization. [Diagram 3] Experimental results showing that different humanized 4E9 antibody clones neutralize IL-4-induced TF-1 proliferation. [Figure 4] 13 shows experimental results that the preferred humanized 4E9 antibody clone neutralizes IL-13-induced TF-1 proliferation. [Diagram 5] These are the experimental results (ELISA) showing that the IL-4Rα / IL-5 bispecific antibody 4E9V10-2B3V2 inhibits the binding of IL-4Rα to IL-4. [Figure 6] These are the experimental results (ELISA) showing that the IL-4Rα / IL-5 bispecific antibody 4E9V10-2B3V2 inhibits the binding of IL-5R to IL-5. [Figure 7] This is the experimental result showing that the IL-4Rα / IL-5 bispecific antibody 4E9V10-2B3V2 neutralizes IL-4-induced TF-1 proliferation. [Figure 8] This is the experimental result showing that the IL-4Rα / IL-5 bispecific antibody 4E9V10-2B3V2 neutralizes IL-13-induced TF-1 proliferation. [Figure 9] This is the experimental result showing that the IL-4Rα / IL-5 bispecific antibody 4E9V10-2B3V2 neutralizes IL-5-induced TF-1 proliferation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0043] In order to make the objectives, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention are described clearly and completely below. If no specific conditions are specified in the embodiments, they are carried out according to normal conditions or conditions recommended by the manufacturers. All reagents or equipment without manufacturer's names are common products available in the market. EXAMPLES
[0044] The features and performance of the present invention will be further illustrated by examples below. [Example 1] Humanization modification Based on the anti-IL-4Rα single domain antibody 4E9 of SEQ ID NO:22 (designated 4E9-V0), humanization was performed.
[0045] The sequences of the humanized and modified humanized single domain antibodies (named 4E9 V1 to V14, respectively) are shown in Table 1, and a comparison of the partially humanized antibody sequences is shown in FIG.
[0046] [Table 1]
[0047] [Example 2] Measurement of neutralization of TF1 cell proliferation induced by IL-4 or IL-13 by humanized single domain antibodies (1) After recovery, TF-1 cells that had been passaged for 3-4 generations were seeded onto a 96-well plate at 10,000 cells / well.
[0048] (2) Different Tabs, humanized single domain antibodies in Table 1 were formulated as 10 μg / mL solutions and serially diluted 5-fold.
[0049] (3) Serially diluted Tab antibody (obtained with reference to the method described in Chinese Patent Application No. CN202010576200.7, titled "Anti-IL-4Rα Single Domain Antibody, and Its Use and Medication") and humanized single domain antibody were mixed with EC80 concentration of IL-4 or IL13 (obtained with reference to the method described in Chinese Patent Application No. CN202010576200.7, titled "Anti-IL-4Rα Single Domain Antibody, and Its Use and Medication") in a 1:1 ratio to prepare a mixture. The definition of EC80 is EC80, which is the concentration for 80% of maximal effect (EC80), and means the concentration that can elicit 80% of the maximum effect.
[0050] (4) The mixture from the previous step was added to the cell culture well in an amount equal to the cell culture solution.
[0051] (5) After 72 h of incubation, cell viability was measured using a luminescent cell viability assay.
[0052] (6) Based on the measurement results, the EC50 concentrations of different humanized single domain antibodies that neutralize IL-4 or IL13-induced TF-1 cell proliferation were calculated. EC50 is the concentration for 50% of maximal effect (EC50), which means the concentration that can elicit 50% of the maximum effect. The results are shown in Tables 2 and 3 and Figures 3 and 4.
[0053] [Table 2]
[0054] [Table 3]
[0055] The results show that among all the humanized antibody sequences, the 4E9-V10 antibody has the highest neutralizing ability against cell proliferation effect, with an EC50 of 0.27 nM, the 4E9-V1 antibody has the lowest effect, and the 4E9-V6, 4E9-V8, 4E9-V12 and 4E9-V13 have some degree of neutralizing effect.
[0056] [Example 3] Measurement of thermal stability of humanized single domain antibodies by differential scanning Experimental Method (1) To an 8-tube strip or a 96-well PCR plate, add 45 μL of the 0.1 mg / mL humanized single domain antibody solution, followed by 5 μL of 100× Sypro orange dye, resulting in a final dye concentration of 5×. Each sample was replicated in triplicate, and 1× PBS was used as a blank. (2) The experimental type was Melt curve, the reporter group was ROX, the quencher group was None, the heating program was 25°C for 5 min, the scanning range was 25 to 95°C, and the heating rate was 1% (approximately 1°C / min). (3) The temperature corresponding to the maximum value of the first derivative of the melting curve was determined to be the denaturation temperature (Tm value) corresponding to the protein.
[0057] The experimental results are shown in Table 4. [Table 4]
[0058] The results show that among all humanized single domain antibodies, 4E9-V13 has the highest thermal stability, 4E9-V3 has the lowest and is undetectable, and 4E9-V10 has the third highest thermal stability among all antibodies.
[0059] [Example 4] Affinity measurement of humanized single domain antibodies Preparation of SD buffer Appropriate amounts of bovine serum albumin and Tween 20 were dissolved in 1×PBS (pH 7.4) so that the mass fraction (or volume fraction) of bovine serum albumin and Tween 20 was 0.1% and 0.02%, respectively. The IL-4Rα binding molecule (the above-mentioned partially humanized single domain antibody) was prepared at a concentration of 10 μg / mL using SD buffer.
[0060] Preparation of antigen working solution The antigen was adjusted to 200 nM in SD buffer and then serially diluted 2-fold to provide five concentration gradients, in addition to which a blank control of SD buffer was set up.
[0061] Preparation of regeneration solution An appropriate amount of 0.1 M glycine stock solution was taken, diluted 10-fold with deionized water, and mixed uniformly to obtain a regenerated solution.
[0062] Experimental procedure Octet 96 and the dedicated computer software Data Acquisiton were started, and an appropriate amount of 75% ethanol was applied to lens cleaning paper to clean the bottom and sides of the collection probe, and the instrument was warmed up for more than 15 minutes. Regarding pre-wetting of the sensor, the sensor was immersed in SD buffer for more than 10 minutes before the start of the experiment in preparation for use, and then the instrument program was set to perform the experimental operation in the following order: baseline → antibody → baseline → antigen binding → antigen dissociation → sensor regeneration. The experimental results are shown in Table 5.
[0063] [Table 5]
[0064] KD is the affinity constant, with units of molar (M). Ka is the binding rate constant, with units of reciprocal molar time (1 / Ms). Kd is the dissociation rate constant, with units of reciprocal time. R 2 R is the degree of fit, i.e., how well the measured curve and the fitted curve match. 2The closer to 1, the closer the fitted value is to the actual value. In this system, R 2 shall be at least greater than 0.95. X 2 is a statistical parameter reflecting the value measured by the system. X 2 is less than 3, and X 2 The smaller the value, the more reliable the measurement. Other error values are the error values of the corresponding parameters and are one order of magnitude (10 times) smaller than the corresponding parameters or smaller.
[0065] As a result, 4E9-V6 and 4E9-V10 are shown to have the lowest KD values and the highest antigen affinity.
[0066] Based on the above results, as well as the results of cellular antibody function assays and physicochemical analyses, 4E9-V10 was found to be the humanized single domain antibody with the highest overall efficacy among all humanized sequences, which was something the inventors had not anticipated. 4E9-V10 was used in the following examples.
[0067] [Example 5] Construction of eukaryotic expression vector for Fc fusion antibody of bispecific single domain antibody of anti-IL-4Rα / IL-5 protein (1) The gene sequence (positions 1 to 345 of SEQ ID NO: 23) of codon-optimized humanized anti-IL-4Rα single domain antibody (4E9V10) and the gene sequence (positions 1069 to 1434 of SEQ ID NO: 23) of humanized anti-IL-5 single domain antibody (named 2B3V2) were synthesized and respectively introduced into vector RJK-V4-3 (obtained with reference to the method described in Chinese patent application no. CN202010576200.7, titled "Anti-IL-4Rα single domain antibody, and uses and medicaments thereof") by sequence synthesis.
[0068] (2) The constructed recombinant eukaryotic expression vector was transformed into DH5α E. coli and cultured to extract the plasmid in large quantities and remove endotoxins.
[0069] (3) A large amount of the extracted plasmid was sequenced and identified.
[0070] (4) The identified anti-IL-4Rα antibody sequence was subcloned into a eukaryotic expression vector containing an anti-IL-5 antibody sequence. Specifically, the anti-IL-4Rα antibody sequence was cut from the eukaryotic expression vector in which it was located with the restriction enzymes XbaI and BamHI, ligated into a eukaryotic expression vector containing an anti-IL-5 antibody sequence with the same restriction enzyme sticky ends, transformed, and identified by sequencing. For the sequenced clone, a large amount of plasmid was extracted and endotoxin was removed. Furthermore, the extracted plasmid was sequenced and identified. The identified recombinant vector was prepared for subsequent eukaryotic cell transfection expression. A eukaryotic expression vector of a bispecific single domain antibody of anti-IL-4Rα / IL-5 protein was obtained. The anti-IL-4Rα / IL-5 protein bispecific single domain antibody (amino acid sequence shown in SEQ ID NO:24, corresponding gene sequence is SEQ ID NO:23) is named 4E9V10-2B3V2 and contains three parts: 4E9V10-Fc region-2B3V2. 4E9V10 is at the amino terminus (positions 1-115 in SEQ ID NO:24), Fc region is at positions 116-356 in SEQ ID NO:24, and 2B3V2 is at the carboxy terminus (positions 357-478 in SEQ ID NO:24).
[0071] [Example 6] The anti-IL-4Rα / IL-5 protein bispecific single domain antibody was expressed in suspension ExpiCHO-S cells using the assay method described in Chinese Patent Application No. CN202010576200.7, entitled "Anti-IL-4Rα Single Domain Antibody and Its Use and Medication."
[0072] [Example 7] The anti-IL-4Rα / IL-5 protein bispecific single domain antibody was expressed in suspension 293F cells using the assay method described in Chinese Patent Application No. CN202010576200.7, entitled "Anti-IL-4Rα Single Domain Antibody and Its Use and Medication."
[0073] [Example 8] The anti-IL-4Rα / IL-5 protein bispecific single domain antibody was purified by the assay method described in Chinese patent application No. CN202010576200.7, entitled "Anti-IL-4Rα single domain antibody and its use and medicament".
[0074] [Example 9] Measurement of receptor-ligand binding inhibition using bispecific single domain antibodies (1) The receptor protein (IL-4Rα or IL-5R) was diluted to 1 μg / mL with protein diluent and coated overnight at 4° C.
[0075] (2) The plates were washed and blocked with 5% non-fat milk at 37°C.
[0076] (3) The ligand protein (IL-4 or IL-5) that binds to biotin was diluted to twice the EC80 concentration, and the antibody was diluted to twice the starting concentration, followed by 5-fold serial dilutions. The ligand protein, diluted antibody (dupilumab, 4E9V10-2B3V2, 4E9-V0 or 2B3 (SEQ ID NO: 25)), and hIgG were transferred to a new preparation plate in a 1:1 ratio and mixed uniformly.
[0077] (4) The plates were washed and the diluted ligand protein / antibody mixtures were transferred to ELISA plates and incubated in duplicate at 37°C.
[0078] (5) The plate was washed, diluted Streptavidin [HRP] was added, and the plate was incubated at 37°C.
[0079] (6) The plate was washed, and single component TMB was added and allowed to develop at room temperature in the dark.
[0080] (7) Stop solution was added, and the values of different well samples were immediately read by a microplate reader at a wavelength of 450 nm and recorded as OD450. EC50 was calculated by plotting. 4E9-V0, non-humanized single domain antibody 2B3 against IL-5, dupilumab, reslizumab, and hIgG were used as controls, and the results are shown in Table 6 and Table 7, Figure 5 and Figure 6, respectively.
[0081] [Table 6]
[0082] [Table 7]
[0083] As a result, it is shown that the humanized bispecific antibodies have comparable inhibitory effects in inhibiting IL-4 / IL-4Rα or IL-5 / IL-5R receptor ligand binding, and are slightly superior, compared to non-humanized antibodies. Also, the humanized bispecific antibodies have roughly equivalent inhibitory abilities, and are slightly superior, compared to the corresponding commercially available drugs.
[0084] [Example 10] Measurement of neutralization of IL-4 or IL-13-induced TF1 cell proliferation by bispecific single domain antibodies See Example 2 for the measurement method.
[0085] The measurement results are shown in Tables 8 and 9 and in Figures 7 and 8.
[0086] [Table 8]
[0087] [Table 9]
[0088] The results show that the humanized bispecific antibodies have comparable, and even slight, inhibitory effects in neutralizing IL-4-induced TF-1 cell proliferation compared to non-humanized antibodies, and are almost equivalent in inhibitory potency compared to the corresponding commercially available drugs.
[0089] [Example 11] Measurement of TF1 cell proliferation induced by human recombinant IL-5 protein and proliferation neutralization by tool antibody (Tab) A. Measurement of TF1 cell proliferation induced by human recombinant IL-5 protein (1) After recovery, TF-1 cells that had been passaged for 3-4 generations were seeded onto a 96-well plate at 10,000 cells / well. (2) Human IL-5 protein was formulated as a solution with a maximum concentration of 500 ng / mL and serially diluted 5-fold. (3) The serially diluted IL-5 protein solutions were added to cell culture wells in an equal volume to the cell culture solution. (4) After 72 h of incubation, cell viability was measured using a luminescent cell viability assay. (5) Based on the measurement results, the EC80 concentration at which IL-5 induces TF-1 cell proliferation was calculated to be 2.96 ng / mL.
[0090] B. Measurement of neutralization of human IL-5-induced TF1 cell proliferation by Tab. (1) After recovery, TF-1 cells that had been passaged for 3-4 generations were seeded onto a 96-well plate at 10,000 cells / well. (2) Tab was formulated as a 10 μg / mL solution and serially diluted 5-fold. (3) Serially diluted Tab was mixed 1:1 with IL-5 at the EC80 concentration obtained in the proliferation experiment to prepare a mixture. (4) The mixture was added to cell culture wells in an amount equal to the cell culture solution. (5) After 72 h of incubation, cell viability was measured using a luminescent cell viability assay. (6) Based on the measurement results, the EC50 concentration of Tab at which IL-5-induced TF-1 cell proliferation was neutralized was calculated.
[0091] [Example 12] Measurement of neutralization of IL-5-induced TF1 cell proliferation by humanized bispecific single domain antibodies (1) After recovery, TF-1 cells that had been passaged for 3-4 generations were seeded onto a 96-well plate at 10,000 cells / well. (2) Tab and the humanized bispecific single domain antibodies were formulated as 10 μg / mL solutions and serially diluted 5-fold. (3) The serially diluted Tab and humanized antibody were mixed 1:1 with the IL-5 protein at the EC80 concentration obtained in Example 13-A to prepare mixed solutions. (4) The mixture was added to cell culture wells in an amount equal to the cell culture solution. (5) After 72 h of incubation, cell viability was measured using a luminescent cell viability assay. (6) Based on the measurement results, the EC50 concentrations of different single domain antibodies to neutralize IL-5-induced TF-1 cell proliferation were calculated. The experimental results are shown in Table 10 and Figure 9.
[0092] [Table 10]
[0093] The results show that the humanized bispecific antibodies have comparable, and even slight, inhibitory effects in neutralizing IL-5-induced TF-1 cell proliferation compared to non-humanized antibodies, and are almost equivalent in inhibitory potency compared to the corresponding commercially available drugs.
[0094] [Example 13] The affinity kinetics of the humanized bispecific antibody was measured by the measurement method shown in Example 4. The measurement results are shown in Table 11.
[0095] [Table 11]
[0096] As a result, the affinities of bispecific antibodies targeting IL4Rα and IL-5 were measured with the two antigens, respectively, and the corresponding affinities were both below 1 nM.
[0097] The above shows and describes the basic principle, main features and advantages of the present invention. The present invention is not limited to the above embodiments, and the above embodiments and the description of the specification are merely for explaining the principles of the present invention. Various modifications and improvements can be made to the present invention without departing from the spirit and scope of the present invention, and it is obvious to those skilled in the art that all of these modifications and improvements are within the scope of protection of the present invention. The scope of protection of the present invention is defined by the appended claims and their equivalents.
Claims
1. A humanized anti-IL-4Rα single domain antibody comprising one of the following combinations: a) CDR1 consisting of the amino acid sequence shown in SEQ ID NO:3, CDR2 consisting of the amino acid sequence shown in SEQ ID NO:12, CDR3 consisting of the amino acid sequence shown in SEQ ID NO:18, FR1 consisting of the amino acid sequence shown in SEQ ID NO:2, FR2 consisting of the amino acid sequence shown in SEQ ID NO:7, FR3 consisting of the amino acid sequence shown in SEQ ID NO:15, and FR4 consisting of the amino acid sequence shown in SEQ ID NO:21; b) CDR1 consisting of the amino acid sequence shown in SEQ ID NO:3, CDR2 consisting of the amino acid sequence shown in SEQ ID NO:12, CDR3 consisting of the amino acid sequence shown in SEQ ID NO:18, FR1 consisting of the amino acid sequence shown in SEQ ID NO:2, FR2 consisting of the amino acid sequence shown in SEQ ID NO:9, FR3 consisting of the amino acid sequence shown in SEQ ID NO:16, and FR4 consisting of the amino acid sequence shown in SEQ ID NO:21; c) CDR1 consisting of the amino acid sequence shown in SEQ ID NO:3, CDR2 consisting of the amino acid sequence shown in SEQ ID NO:12, CDR3 consisting of the amino acid sequence shown in SEQ ID NO:18, FR1 consisting of the amino acid sequence shown in SEQ ID NO:2, FR2 consisting of the amino acid sequence shown in SEQ ID NO:10, FR3 consisting of the amino acid sequence shown in SEQ ID NO:15, and FR4 consisting of the amino acid sequence shown in SEQ ID NO:21; d) CDR1 consisting of the amino acid sequence shown in SEQ ID NO:3, CDR2 consisting of the amino acid sequence shown in SEQ ID NO:12, CDR3 consisting of the amino acid sequence shown in SEQ ID NO:18, FR1 consisting of the amino acid sequence shown in SEQ ID NO:2, FR2 consisting of the amino acid sequence shown in SEQ ID NO:11, FR3 consisting of the amino acid sequence shown in SEQ ID NO:15, and FR4 consisting of the amino acid sequence shown in SEQ ID NO:21; e) a CDR1 consisting of the amino acid sequence shown in SEQ ID NO:3, a CDR2 consisting of the amino acid sequence shown in SEQ ID NO:12, a CDR3 consisting of the amino acid sequence shown in SEQ ID NO:18, a FR1 consisting of the amino acid sequence shown in SEQ ID NO:2, a FR2 consisting of the amino acid sequence shown in SEQ ID NO:7, a FR3 consisting of the amino acid sequence shown in SEQ ID NO:16, and a FR4 consisting of the amino acid sequence shown in SEQ ID NO:21; or f) CDR1 consisting of the amino acid sequence shown in SEQ ID NO:3, CDR2 consisting of the amino acid sequence shown in SEQ ID NO:12, CDR3 consisting of the amino acid sequence shown in SEQ ID NO:18, FR1 consisting of the amino acid sequence shown in SEQ ID NO:2, FR2 consisting of the amino acid sequence shown in SEQ ID NO:7, FR3 consisting of the amino acid sequence shown in SEQ ID NO:17, and FR4 consisting of the amino acid sequence shown in SEQ ID NO:
21.
2. A humanized anti-IL-4Rα single domain antibody as described in claim 1, characterized in that the amino acid sequence of CDR1 is shown in SEQ ID NO: 3, the amino acid sequence of CDR2 is shown in SEQ ID NO: 12, the amino acid sequence of CDR3 is shown in SEQ ID NO: 18, the amino acid sequence of FR1 is shown in SEQ ID NO: 2, the amino acid sequence of FR2 is shown in SEQ ID NO: 11, the amino acid sequence of FR3 is shown in SEQ ID NO: 15, and the amino acid sequence of FR4 is shown in SEQ ID NO:
21.
3. A fusion protein comprising the anti-IL-4Rα single domain antibody according to claim 1 or 2.
4. A bispecific antibody comprising the anti-IL-4Rα single domain antibody according to claim 1 or 2.
5. The bispecific antibody of claim 4 further comprising an anti-IL-5 single domain antibody.
6. The bispecific antibody of claim 5 , wherein the bispecific antibody is represented by SEQ ID NO:
24.
7. A nucleic acid molecule encoding the bispecific antibody of any one of claims 4 to 6, having the nucleotide sequence shown in SEQ ID NO:
23.
8. Use of an anti-IL-4Rα single domain antibody according to claim 1 or 2, a fusion protein according to claim 3, or a bispecific antibody according to any of claims 4 to 6 in the preparation of a drug targeting IL-4Rα for treating a disease.
9. 9. The use according to claim 8, characterized in that the disease is selected from asthma, allergic dermatitis, eczema, arthritis, herpes, chronic idiopathic urticaria, scleroderma, hypertrophic scars, chronic obstructive pulmonary disease, atopic dermatitis, idiopathic pulmonary fibrosis, Kawasaki disease, sickle cell disease, Graves' disease, Sjogren's syndrome, autoimmune lymphoproliferative syndrome, autoimmune hemolytic anemia, Barrett's esophagus, autoimmune uveitis, tuberculosis, and kidney disease.
10. A drug for treating a disease, comprising an anti-IL-4Rα single domain antibody according to claim 1 or 2, a fusion protein according to claim 3, or a bispecific antibody according to any one of claims 4 to 6, and a pharma- ceutically acceptable excipient.
11. An isolated nucleic acid molecule encoding the anti-IL-4Rα single domain antibody according to claim 1 or 2.
12. A vector or recombinant cell comprising the nucleic acid molecule of claim 11.
13. A method for preparing the anti-IL-4Rα single domain antibody according to claim 1 or 2, comprising the steps of culturing a recombinant cell and isolating and purifying the single domain antibody from the culture product, wherein the recombinant cell contains a recombinant expression vector comprising the nucleic acid molecule according to claim 11.
Citation Information
Patent Citations
Anti-IL-4R alpha single-domain antibody, application and drug
CN111690066A
synthetic single domain antibody
JP2016535093A
Humanized antibodies that cross the blood-brain barrier and uses thereof
JP2019525743A
Single domain antibodies against CTLA-4 and their variants
JP2019533719A
Combined antagonists against il-5 / il-5r and either il-4 / il-4r or il-13 / il-13r
WO2019158728A1
